Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Xếp hạng trong cổ phiếu #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Giá cổ phiếu
$1.69
Đồng bộ lần cuối: 2026-09-02
Vốn hóa thị trường
$216.83M
Thay đổi (1 ngày)
3.38%
Thay đổi (1 năm)
-66.03%
Quốc gia
US
Giao dịch Organogenesis Holdings Inc. (ORGO)

Danh mục

Doanh thu của Organogenesis Holdings Inc. (ORGO)
Doanh thu vào Sep 2026 TTM: 0
Theo các báo cáo tài chính gần đây của Organogenesis Holdings Inc., doanh thu hiện tại của công ty (TTM) là 0. Trong năm 2026, công ty đạt doanh thu 0 bằng với doanh thu năm 2026, là 0. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Organogenesis Holdings Inc. từ 2026 đến 2026
Doanh thu vào cuối mỗi năm
Năm Doanh thu Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.
Doanh thu của các công ty hoặc đối thủ tương tự